Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3 .

Mark J Levis Mehdi Hamadani Brent R LoganRichard J JonesAnurag K SinghMark R Litzow John R WingardEsperanza B PapadopoulosAlexander E Perl Robert J Soiffer Celalettin Ustun Masumi Ueda Oshima Geoffrey L Uy Edmund K WallerSumithra VasuMelham M Solh Asmita Mishra Lori S Muffly Hee-Je KimJan-Henrik MikeschYuho Najima Masahiro OnozawaKirsty ThomsonArnon Nagler Andrew H WeiGuido MarcucciNancy L GellerNahla HasabouDavid DelgadoMatt RosalesJason E Hill Stanley C GillRishita NuthethiDenise KingHeather WittsackAdam MendizabalSteven M Devine Mary M Horowitz Yi-Bin Chennull null

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.

Keyphrases

acute myeloid leukemia
randomized controlled trial
cell cycle arrest
systematic review
electronic health record
big data
stem cells
cell death
machine learning
combination therapy
artificial intelligence